Please use this identifier to cite or link to this item:
https://swslhd.intersearch.com.au/swslhdjspui/handle/1/9520
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gofton, C. | - |
dc.contributor.author | Upendran, Y. | - |
dc.contributor.author | Zheng, M. H. | - |
dc.contributor.author | George, J. | - |
dc.date.accessioned | 2023-08-18T05:07:51Z | - |
dc.date.available | 2023-08-18T05:07:51Z | - |
dc.date.issued | 2023 | - |
dc.identifier.issn | 22872728 (ISSN) | - |
dc.identifier.uri | https://swslhd.intersearch.com.au/swslhdjspui/handle/1/9520 | - |
dc.description.abstract | ?Metabolic dysfunction-associated fatty liver disease (MAFLD)? is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research. ? 2023 by Korean Association for the Study of the Liver. | - |
dc.publisher | Korean Association for the Study of the Liver | - |
dc.subject | MAFLD MAFLD vs. NAFLD NAFLD awareness body mass false positive result fatty liver high risk behavior human liver disease metabolic fatty liver metabolic syndrome X mortality nomenclature nonalcoholic fatty liver phenotype prevalence Review risk factor stigma synergistic effect | - |
dc.title | MAFLD: How is it different from NAFLD? | - |
dc.type | Journal Article | - |
dc.contributor.swslhdauthor | Gofton, Cameron | - |
dc.description.affiliates | Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, Australia Department of Gastroenterology and Hepatology, Royal North Shore Hospital, St Leonards, NSW, Australia Department of Gastroen-terology and Hepatology, Bankstown-Lidcombe Hospital, Bankstown, NSW, Australia Department of Gastroenterology and Hepatology, University of New South Wales, Sydney, NSW, Australia MAFLD Research Center, Department of Hepatology, the First Affili-ated Hospital of Wenzhou Medical University, Wenzhou, China Wenzhou Key Laboratory of Hepatology, Wenzhou, China Institute of Hepa-tology, Wenzhou Medical University, Wenzhou, China Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China | - |
dc.identifier.doi | 10.3350/cmh.2022.0367 | - |
dc.identifier.department | Bankstown-Lidcombe Hospital, Department of Gastroenterology & Hepatology | - |
dc.type.studyortrial | Review | - |
dc.identifier.journaltitle | Clinical and Molecular Hepatology | - |
Appears in Collections: | Bankstown-Lidcombe Hospital |
Files in This Item:
There are no files associated with this item.
Items in Prosentient are protected by copyright, with all rights reserved, unless otherwise indicated.